These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Bispecific antibodies for cancer therapy. Hollander N Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943 [TBL] [Abstract][Full Text] [Related]
5. Current perspectives of bispecific antibody-based immunotherapy. Talac R; Nelson H J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049 [TBL] [Abstract][Full Text] [Related]
6. Recombinant bispecific antibodies for cancer therapy. Kontermann RE Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107 [TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies in cancer immunotherapy. Chen S; Li J; Li Q; Wang Z Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163 [TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies for viral immunotherapy. Nyakatura EK; Soare AY; Lai JR Hum Vaccin Immunother; 2017 Apr; 13(4):836-842. PubMed ID: 27786606 [TBL] [Abstract][Full Text] [Related]
10. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening. Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411 [TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Yang F; Wen W; Qin W Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020 [TBL] [Abstract][Full Text] [Related]
14. Recombinant bispecific antibodies for cellular cancer immunotherapy. Müller D; Kontermann RE Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Kipriyanov SM; Le Gall F Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258 [TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibody Armed T Cells to Target Cancer Cells. Thakur A; Lum LG; Mittal S Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802 [TBL] [Abstract][Full Text] [Related]
17. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. Dimasi N; Fleming R; Sachsenmeier KF; Bezabeh B; Hay C; Wu J; Sult E; Rajan S; Zhuang L; Cariuk P; Buchanan A; Bowen MA; Wu H; Gao C MAbs; 2017 Apr; 9(3):438-454. PubMed ID: 28055299 [TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody derivatives based on full-length IgG formats. Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106 [TBL] [Abstract][Full Text] [Related]
19. Bispecific antibodies for cancer immunotherapy: Current perspectives. Müller D; Kontermann RE BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124 [TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effect of bispecific antibody targeting IL-12 p40 and TNF-α simultaneously on psoriasis in mice]. Xu P; Xie N; Ye C Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):890-895. PubMed ID: 28712395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]